Post-kala-azar dermal leishmaniasis: Recent developments

International Journal of Dermatology

Volumn 50, Issue 9, 2011, Pages 1099-1108

  Singh, Sarman ^a   Sharma, Umakant ^a   Mishra, Jyotsna ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANTIMONY GLUCONATE; GAMMA INTERFERON; GAMMA INTERFERON RECEPTOR; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G3; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; ITRACONAZOLE; KETOCONAZOLE; MILTEFOSINE; NYSTATIN; PENTAMIDINE; RIFAMPICIN; STIBOGLUCONATE SODIUM; TERBINAFINE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TRANSFORMING GROWTH FACTOR BETA;

AFRICA; AGGLUTINATION TEST; AMPLICON; ARTICLE; BLINDNESS; CD3+ T LYMPHOCYTE; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CYTOKINE RESPONSE; DECREASED APPETITE; DRUG FEVER; DRUG MEGADOSE; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHEMA; GENE EXPRESSION PROFILING; GENETIC HETEROGENEITY; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMORAL IMMUNITY; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; LEISHMANIA CHAGASI; LEISHMANIA DONOVANI; LEISHMANIA INFANTUM; MACULOPAPULAR RASH; MOLECULAR EPIDEMIOLOGY; NEPHROTOXICITY; NONHUMAN; NUCLEIC ACID SEQUENCE BASED AMPLIFICATION; PAPULE; PARASITE TRANSMISSION; PATHOGENESIS; POST KALA AZAR DERMAL LEISHMANIASIS; REAL TIME POLYMERASE CHAIN REACTION; REINFECTION; SENSITIVITY AND SPECIFICITY; SHIVERING; SKIN LEISHMANIASIS; SKIN NODULE; STRAIN IDENTIFICATION; TH1 CELL; TH2 CELL; UNSPECIFIED SIDE EFFECT; WESTERN BLOTTING;

HUMANS; IMMUNOLOGIC TESTS; LEISHMANIA INFANTUM; LEISHMANIASIS, CUTANEOUS; LEISHMANIASIS, VISCERAL; MOLECULAR DIAGNOSTIC TECHNIQUES;

EID: 80051881079     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2011.04925.x     Document Type: Article

References (61)

1. Sacks DL, Kenney RT, Kreutzer RD, et al. Indian kala-azar caused by Leishmania tropica. Lancet 1995; 345: 959-961.
2. Brahmachari UN. A new form of cutaneous leishmaniasis-dermal leishmanoid. Ind Med Gaz 1922; 57: 125.
3. Ramesh V, Mukherjee A. Post-kala-azar dermal leishmaniasis. Int J Dermatol 1995; 34: 85-91.
4. Zijlstra EE, El-Hassan AM. Leishmaniasis in Sudan: post kala-azar dermal leishmaniasis. Trans R Soc Trop Med Hyg 2001; 95: S59-S76.
5. Zijlstra EE, Musa AM, Khalil EA, et al. Post-kala-azar dermal leishmaniasis. Lancet Infect Dis 2003; 3: 87-98.
6. Bittencourt A, Silva N, Straatmann A, et al. Post-kala-azar dermal leishmaniasis associated with AIDS. Braz J Infect Dis 2002; 6: 313-316.
7. Khandpur S, Ramam M, Sharma VK, et al. Nerve involvement in Indian post-kala-azar dermal leishmaniasis. Acta Derm Venereol 2004; 84: 245-246.
8. Thakur CP, Kumar A, Mitra G, et al. Impact of amphotericin B in the treatment of kala-azar on the incidence of PKDL in Bihar, India. Indian J Med Res 2008; 128: 38-44.
9. Singh S, McGwire BS, Chang KP. Kinetoplast and nuclear DNA polymorphism of visceral Leishmania isolates from North-eastern India. J Protozool Res 1995; 5: 27-32.
10. Dey A, Singh S. Genetic heterogeneity among visceral and post-kala-azar dermal leishmaniasis strains from eastern India. Infect Genet Evol 2007; 7: 219-222.
11. Subbaraju BV, Singh R, Sreenivas G, et al. Genetic fingerprinting and identification of differentially expressed genes in isolates of Leishmania donovani from Indian patients of post-kala-azar dermal leishmaniasis. Parasitology 2008; 135: 23-32.
12. Kumar D, Ramesh V, Verma S, et al. Post-kala-azar dermal leishmaniasis (PKDL) developing after treatment of visceral leishmaniasis with amphotericin B and miltefosine. Ann Trop Med Parasitol 2009; 103: 727-730.
13. Elshafie AI, Ahlin E, Mathsson L, et al. Circulating immune complexes (IC) and IC-induced levels of GM-CSF are increased in Sudanese patients with acute visceral Leishmania donovani infection undergoing sodium stibogluconate treatment: implications for disease pathogenesis. J Immunol 2007; 178: 5383-5389.
14. Saha S, Mondal S, Ravindran R, et al. IL-10- and TGF-β-mediated susceptibility in kala-azar and post-kala-azar dermal leishmaniasis: the significance of amphotericin B in the control of Leishmania donovani infection in India. J Immunol 2007; 179: 5592-5603.
15. Zijlstra EE, Khalil EAG, Kager PA, El-Hassan AM. Post-kala-azar dermal leishmaniasis in the Sudan: clinical presentation and differential diagnosis. Br J Dermatol 2000; 142: 136-143.
16. Thakur CP, Narain S, Kumar N, et al. Amphotericin B is superior to sodium antimony gluconate in the treatment of Indian post-kala-azar dermal leishmaniasis. Ann Trop Med Parasitol 1997; 91: 611-616.
17. Karp CL, el-Safi SH, Wynn TA, et al. In vivo cytokine profiles in patients with kala-azar: marked elevation of both interleukin-10 and IFN-γ. J Clin Invest 1993; 91: 1644-1648.
18. Haldar JP, Ghose S, Saha KC, Ghosei AC. Cell-mediated immune response in Indian kala azar and post-kala azar dermal leishmaniasis. Infect Immun 1983; 42: 702-707.
19. Gasim S, El Hassan AM, Khalil EA, et al. High levels of plasma IL-10 and expression of IL-10 by keratinocytes during visceral leishmaniasis predict subsequent development of post-kala-azar dermal leishmaniasis. Clin Exp Immunol 1998; 111: 64-69.
20. Sreenivas G, Raju SBV, Singh R, et al. DNA polymorphism assay distinguishes isolates of Leishmania donovani that cause kala-azar from those that cause post-kala-azar dermal leishmaniasis in humans. J Clin Microbiol 2004; 42: 1739-1741.
21. Schonian G, El Fari M, Lewin S, et al. Molecular epidemiology and population genetics in Leishmania. Med Microbiol Immunol (Berl) 2001; 190: 61-63.
22. Salotra P, Duncan RC, Singh R, et al. Upregulation of surface proteins in Leishmania donovani isolated from patients of post kala-azar dermal leishmaniasis. Microbes Infect 2006; 8: 637-644.
23. Saha S, Mazumdar T, Anam K, et al. Leishmania promastigote membrane antigen based enzyme linked immunosorbent assay and immunoblotting for differential diagnosis of Indian post-kalaazar dermal leishmaniasis. J Clin Microbiol 2005; 43: 1269-1277.
24. Ganguly S, Das NK, Panja M, et al. Increased levels of interleukin-10 and IgG3 are hallmarks of Indian post-kala-azar dermal leishmaniasis. J Infect Dis 2008; 197: 1762-1771.
25. Ansari NA, Katara GK, Ramesh V, Salotra P. Evidence for involvement of TNFR1 and TIMPs in pathogenesis of post-kala-azar dermal leishmaniasis. Clin Exp Immunol 2008; 154: 391-398.
26. Lacraz S, Nicod LP, Chicheportiche R, et al. IL-10 inhibits metalloproteinase and stimulates TIMP-1 production in human mononuclear phagocytes. J Clin Invest 1995; 6: 2304-2310.
27. Vaday GG, Schor H, Rahat MA, et al. Transforming growth factor-beta suppresses tumor necrosis factor alpha-induced matrix metalloproteinase-9 expression in monocytes. J Leukoc Biol 2001; 69: 613-621.
28. Rioux JA, Lanotte G, Serres E, et al. Taxonomy of Leishmania. Use of isoenzymes. Suggestions for a new classification. Ann Parasitol Hum Comp 1990; 65: 111-125.
29. Pratlong F, Dereure J, Bucheton B, et al. Sudan: the possible original focus of visceral leishmaniasis. Parasitology 2001; 122: 599-605.
30. Zijlstra EE, Nur Y, Desjeux P, et al. Diagnosing visceral leishmaniasis with the recombinant k39 strip test: experience from the Sudan. Trop Med Int Health 2001; 6: 108-113.
31. Sivakumar R, Dey A, Sharma P, Singh S. Expression and characterization of a recombinant kinesin antigen from an old Indian strain (DD8) of Leishmania donovani and comparing it with a commercially available antigen from a newly isolated (KE16) strain of L. donovani. Infect Genet Evol 2008; 8: 313-322.
32. Sharma MC, Gupta AK, Verma N, et al. Demonstration of Leishmania parasites in skin lesions of Indian post kala-azar dermal leishmaniasis (PKDL) cases. J Commun Dis 2000; 32: 67-68.
33. Singh N, Ramesh V, Arora VK, et al. Nodular post kala-azar dermal leishmaniasis: a distinct histopathological entity. J Cutan Pathol 1998; 25: 95-99.
34. Beena KR, Ramesh V, Mukherjee A. Identification of parasite antigen, correlation of parasite density and inflammation in skin lesions of post kala-azar dermal leishmaniasis. J Cutan Pathol 2003; 30: 616-620.
35. Singh RP. Observation on dermal leishmanoid in Bihar. Indian J Dermatol 1968; 13: 59-63.
36. Singh S, Kumari V, Singh N. Predicting kala-azar disease manifestations in asymptomatic patients with latent Leishmania donovani infection by detection of antibody against recombinant K39 antigen. Clin Diagn Lab Immunol 2002; 9: 568-572.
37. Maalej IA, Chenik M, Louzir H, et al. Comparative evaluation of ELISAs based on ten recombinant or purified Leishmania antigens for the serodiagnosis of mediterrean visceral lesihmaniasis. Am J Trop Med Hyg 2003; 68: 312-320.
38. Badaro R, Benson D, Eulalio MC, et al. rK39: a cloned antigen of Leishmania chagasi that predicts active visceral leishmaniasis. J Infect Dis 1996; 173: 758-761.
39. Singh S, Gilman-Sachs A, Chang KP, Reed SG. Diagnostic and prognostic value of K39 recombinant antigen in Indian leishmaniasis. J Parasitol 1995; 81: 1000-1003.
40. Houghton RL, Petrescu M, Benson DR, et al. A cloned antigen (recombinant K39) of Leishmania chagasi diagnostic for visceral leishmaniasis in human immunodeficiency virus type 1 patients and a prognostic indicator for monitoring patients undergoing drug therapy. J Infect Dis 1998; 177: 1339-1344.
41. Singh S, Dey A, Sivakumar R. Applications of molecular methods for Leishmania control. Expert Rev Mol Diagn 2005; 5: 251-265.
42. Harith AE, Chowdhury S, Al-Masum A, et al. Reactivity of various Leishmanial antigens in a direct agglutination test and their value in differentiating post-kala azar dermal leishmaniasis from leprosy and other skin conditions. J Med Microbiol 1996; 44: 141-146.
43. Tavares CAP, Fernandes AP, Melo MN. Molecular diagnosis of leishmaniasis. Expert Rev Mol Diagn 2003; 3: 657-667.
44. Sreenivas G, Ansari NA, Kataria J, Salotra P. Nested PCR assay for detection of Leishmania donovani in slit aspirates from post-kala-azar dermal leishmaniasis lesions. J Clin Microbiol 2004; 42: 1777-1778.
45. Osman OF, Oskam L, Kroon NC, et al. Use of PCR for diagnosis of post-kala azar dermal leishmaniasis. J Clin Microbiol 1998; 36: 1621-1624.
46. Mary C, Faraut F, Lascombe L, Dumon H. Quantification of Leishmania infantum DNA by a real-time PCR assay with high sensitivity. J Clin Microbiol 2004; 42: 5249-5255.
47. Bossolasco S, Gaiera G, Olchini D, et al. Real-time PCR assay for clinical management of human immunodeficiency virus-infected patients with visceral leishmaniasis. J Clin Microbiol 2003; 41: 5080-5084.
48. Schulz A, Mellenthin K, Schonian G, et al. Detection, differentiation, and quantitation of pathogenic Leishmania organisms by a fluorescence resonance energy transfer-based real-time PCR assay. J Clin Microbiol 2003; 41: 1529-1535.
49. Van der Meide WF, Schoone GJ, Faber WR, et al. Quantitative nucleic acid sequence-based assay as a new molecular tool for detection and quantification of Leishmania parasites in skin biopsy samples. J Clin Microbiol 2005; 43: 5560-5566.
50. Victoir K, de Doncker S, Cabrera L, et al. Direct identification of Leishmania species in biopsies from patients with American tegumentary leishmaniasis. Trans R Soc Trop Med Hyg 2003; 97: 80-87.
51. Das Gupta S, Ghosh DK, Majumder HK. A cloned kinetoplast DNA mini-circle fragment from a Leishmania spp. specific for post-kala-azar dermal leishmaniasis strains. Parasitology 1991; 102: 187-191.
52. Musa AM, Khalil EAG, Raheem MA, et al. The natural history of Sudanese post-kala-azar dermal leishmaniasis: clinical, immunological and prognostic features. Ann Trop Med Parasitol 2002; 96: 765-772.
53. Thakur CP, Kumar K. Efficacy of prolonged therapy with stibogluconate in post kala-azar dermal leishmaniasis. Indian J Med Res 1990; 91: 144-148.
54. Thakur CP. Epidemiological, clinical and therapeutic features of bihar kala-azar (including post kala-azar dermal leishmaniasis). Trans R Soc Trop Med 1984; 78: 391-398.
55. Ramesh V, Saxena U, Misra RS. Efficacy of ketoconazole in post-kala-azar dermal leishmaniasis. Arch Dermatol 1992; 128: 411-412.
56. Saha SK. Dermal leishmaniasis after kala-azar infection: successful treatment with rifampin. Cutis 1985; 36: 81-82.
57. Ramesh V. Allopurinol therapy in post-kala-azar dermal leishmaniasis. Acta Derm Venereol 1996; 76: 328-329.
58. Khalil EAG, Nur NM, Zijlstra EE, et al. Failure of a combination of two antifungal drugs, terbinafine and itraconazole, in Sudanese post kala-azar dermal leishmaniasis. Trans R Soc Trop Med Hyg 1996; 90: 187-188.
59. Ramesh V, Ansari NA, Jain RK, Salotra P. Oral miltefosine in the treatment of post-kala-azar dermal leishmaniasis. Clin Exp Dermatol 2008; 33: 103-105.
60. Schmidt-Ott R, Klenner T, Overath P, Aebischer T. Topical treatment with hexadecylphosphocholine (Miltex R) efficiently reduces parasite burden in experimental cutaneous leishmaniasis. Trans R Soc Trop Med Hyg 1999; 93: 85-90.
61. Musa AM, Khalil EA, Mahgoub FA, et al. Immunochemotherapy of persistent post-kala-azar dermal leishmaniasis: a novel approach to treatment. Trans R Soc Trop Med Hyg 2008; 102: 58-63.